Pelthos Therapeutics (PTHS) director receives 12,000 RSUs under 2023 plan

Rhea-AI Filing Summary

Pelthos Therapeutics Inc. reported an equity compensation grant to director Andrew J. Einhorn. On December 23, 2025, he was awarded 12,000 Restricted Stock Units (RSUs) of Pelthos common stock under the company’s 2023 Equity Incentive Plan, as amended and restated effective April 16, 2025. Each RSU represents a contingent right to receive one share of common stock with a par value of $0.0001 per share. The RSUs are scheduled to vest on January 1, 2027, meaning the shares will be delivered only if the vesting conditions tied to board service are satisfied.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Einhorn Andrew J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	12,000	$0.00	--

Holdings After Transaction: Common Stock — 12,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Einhorn Andrew J.

(Last) (First) (Middle)

C/O PELTHOS THERAPEUTICS INC.

4020 STIRRUP CREEK DRIVE, SUITE 110

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pelthos Therapeutics Inc. [ PTHS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	12/23/2025		A		12,000	A	(1)	12,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On December 23, 2025, the Reporting Person was granted 12,000 Restricted Stock Units (the "RSUs") of the issuer, as compensation for the Reporting Person's service as a member of the issuer's board of directors, pursuant to the issuer's 2023 Equity Incentive Plan, as amended and restated effective as of April 16, 2025 (the "Plan"). The RSUs will vest on January 1, 2027. Each RSU represents a contingent right to receive one share of issuer's Common Stock, par value $0.0001 per share.

	/s/ Andrew J. Einhorn	12/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction was reported for Pelthos Therapeutics Inc. (PTHS)?

A director, Andrew J. Einhorn, reported receiving 12,000 Restricted Stock Units (RSUs) of Pelthos Therapeutics Inc. common stock as equity compensation.

When were the 12,000 RSUs granted to the Pelthos (PTHS) director?

The 12,000 RSUs were granted on December 23, 2025 as compensation for service on the board of directors.

When do the Pelthos (PTHS) RSUs granted to the director vest?

The 12,000 RSUs granted to the director will vest on January 1, 2027, at which point the underlying shares are scheduled to be delivered.

What does each RSU granted by Pelthos Therapeutics (PTHS) represent?

Each RSU represents a contingent right to receive one share of Pelthos Therapeutics Inc. common stock, par value $0.0001 per share.

Under which plan were the Pelthos (PTHS) RSUs granted to the director?

The RSUs were granted under Pelthos Therapeutics Inc.’s 2023 Equity Incentive Plan, as amended and restated effective as of April 16, 2025.

How many Pelthos (PTHS) shares does the director report beneficially owning after the transaction?

Following the grant, the director reports beneficial ownership of 12,000 shares of Pelthos Therapeutics Inc. common stock, held directly.